Merck & Co., Inc. Debt and Equity Securities, Gain (Loss)
Merck & Co., Inc. (MRK) reported Debt and Equity Securities, Gain (Loss) of $80.00 million for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-06.
Discontinued › Income Statement › Other Income
us-gaap:DebtAndEquitySecuritiesGainLoss · last filed 2018-11-06
- Merck & Co., Inc. debt and equity securities, gain (loss) for the quarter ending 2018-09-30 was $80.00M, a 220.00% increase year-over-year.
- Merck & Co., Inc. debt and equity securities, gain (loss) for the quarter ending 2017-09-30 was $25.00M.
| Period end | Debt and Equity Securities, Gain (Loss) 3 month | Debt and Equity Securities, Gain (Loss) 9 month |
|---|---|---|
| 2018-09-30 | $80.00M 10-Q · filed 2018-11-06 | $202.00M 10-Q · filed 2018-11-06 |
| 2017-09-30 | $25.00M 10-Q · filed 2018-11-06 | $74.00M 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |